Medical Oncologist
Targeted therapy · Prostate cancer
Targeted Therapy for — Prostate Cancer
Targeted therapy for prostate cancer is not for everyone — it depends on finding a specific mutation in your tumour. The most important first step is genetic testing, because that is what decides whether this type of treatment applies to you.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Mutation first, treatment second — Targeted therapy works only where a specific mutation is present. Testing tells you whether it applies to your cancer.
- Two types of testing — A blood test checks for inherited mutations. Tumour tissue testing checks for mutations the cancer acquired on its own.
- BRCA1 and BRCA2 matter most — These two mutations predict response to PARP inhibitors, the main targeted drug class in prostate cancer right now.
- A negative result is still an answer — Not finding a mutation means other proven paths — hormone therapy, chemotherapy, radiation — remain your best options.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy for prostate cancer works by finding specific gene mutations in your tumour — most often BRCA1, BRCA2 or ATM — and using drugs designed to exploit them. NCCN recommends genetic testing for all metastatic prostate cancer. Not every patient has a mutation, but those who do may have additional treatment options.
How does the testing and treatment pathway work?
Your oncologist recommends genetic testing
At diagnosis of metastatic prostate cancer, NCCN and ESMO both recommend offering germline and somatic genetic testing. Your oncologist explains what is being looked for and why.
A blood sample is taken for germline testing
This checks for mutations you were born with, including BRCA1 and BRCA2. A positive result also has implications for your blood relatives, which your oncologist or a genetic counsellor will explain.
Tumour tissue is sent for somatic testing
The biopsy sample already taken from your prostate or a metastatic site is tested using next-generation sequencing to look for mutations the cancer acquired — including HRR genes, MSI status and tumour mutational burden.
Results come back in approximately two to three weeks
The laboratory returns a report listing which mutations were found and which were not. Your oncologist interprets this in the context of your specific diagnosis and stage.
Your oncologist explains what the result means for treatment
If a targetable mutation is found, your treatment plan is discussed. If not, you continue on the most effective path for your cancer type — and your oncologist can tell you whether any clinical trials apply.
Which mutations and markers are tested in prostate cancer?
- BRCA1 and BRCA2 — the most clinically important; predict response to PARP inhibitors
- ATM — a homologous recombination repair gene tested alongside BRCA
- CDK12 — associated with a specific pattern of genomic instability in prostate cancer
- PALB2 and CHEK2 — less common HRR gene mutations included in most panels
- Microsatellite instability-high (MSI-H) — rare in prostate cancer but clinically important when present
- Tumour mutational burden (TMB-H) — a broader marker of genomic instability
- NTRK gene fusions — very rare, but targetable across cancer types when identified
What are PARP inhibitors and who are they for?
PARP inhibitors are a class of targeted drugs that block a DNA-repair mechanism that cancer cells with HRR gene mutations — including BRCA1, BRCA2 and ATM — depend on to survive.
When a prostate cancer cell has a defect in this repair pathway, it cannot fix the DNA damage that PARP inhibitors cause, and it dies. Normal cells, which have intact repair systems, are much less affected.
NCCN and ESMO both list PARP inhibitors as a recommended option for metastatic castration-resistant prostate cancer in patients whose tumours carry qualifying HRR gene mutations. Your oncologist will tell you whether your specific mutation is one that meets the current criteria.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What if your tumour shows MSI-H or TMB-H?
A small proportion of prostate cancers show microsatellite instability-high status or a high tumour mutational burden. These mark a different kind of genomic instability, not the HRR pathway that PARP inhibitors target.
For MSI-H and TMB-H tumours, immunotherapy is the indicated approach, as per NCCN, ASCO and ESMO guidance — a meaningfully different treatment path from the PARP inhibitor route, even though both begin with biomarker testing.
These findings are uncommon in prostate cancer. If your result comes back this way, your oncologist will explain what it means for your treatment plan specifically.
What if testing does not find a targetable mutation?
A negative result does not mean you are out of options. It means that targeted therapy in its current form is not the right tool for your cancer.
Prostate cancer has several effective systemic treatments — including hormone therapy agents that target the androgen receptor pathway, chemotherapy, and bone-targeting treatments — that do not require a mutation to work.
Testing also continues to evolve. Mutations that are not targetable today may become so as new trials reach approval. Ask your oncologist whether any clinical trials are relevant to your result.
Questions families ask about targeted therapy for prostate cancer
If I have a BRCA mutation, does that affect my children and siblings?
A germline BRCA mutation is inherited, which means it is present in every cell in your body from birth — not just in the cancer. Each first-degree relative, meaning a child, sibling or parent, has a one in two chance of carrying the same mutation. Your oncologist or a genetic counsellor will explain what relatives should do and what kind of testing they should consider. This is one of the most important conversations to have when a germline result comes back, and it is reasonable to ask for a referral to genetic counselling.
What is the difference between a germline test and a tumour tissue test?
A germline test is done on your blood and checks for mutations you were born with — ones that are present in every cell and can be passed to your children. A somatic test is done on tumour tissue and checks for mutations the cancer acquired over time. These are present only in the tumour and are not inherited. Both types of mutation can predict whether targeted therapy is likely to work, but they have very different implications for your family. Testing for both is recommended for most patients with metastatic prostate cancer.
Does targeted therapy replace hormone therapy for prostate cancer?
Not usually. Hormone therapy — which lowers androgen levels or blocks the androgen receptor — remains the central treatment for most stages of advanced prostate cancer. PARP inhibitors are typically added to, or given after, hormone therapy, depending on your stage and your mutation status. They target a different biological pathway. Your oncologist will explain where targeted therapy fits in the sequence for you, because the order and combination both affect how well treatment works overall.
How much does targeted therapy cost in India?
Costs vary considerably between hospitals, cities and the specific drug prescribed, and any figure given here would be indicative and quickly outdated. PARP inhibitors are generally at the higher end of cancer medicine costs. Some patients access them through clinical trials at no direct cost, and others through manufacturer patient-access programmes. Your oncology team at CION can advise on what costs to expect, what health insurance may cover in your case, and whether any access schemes are available for your situation.
Can I have targeted therapy if my prostate cancer has not spread yet?
Current NCCN and ESMO guidance for PARP inhibitors in prostate cancer is focused on metastatic castration-resistant disease. Genetic testing may still be recommended at earlier stages — particularly if there is a family history suggesting a hereditary BRCA mutation — but it is often done to inform future decisions rather than to open a treatment immediately. Whether targeted therapy is appropriate now, or whether testing is being done to plan ahead, depends on your specific stage and history. Ask your oncologist which situation applies to you.
Is targeted therapy for prostate cancer available at CION?
CION oncologists assess eligibility for targeted therapy and coordinate the biomarker testing needed to determine it. Targeted therapy, where indicated, is administered as day care at CION centres. CION does not provide CAR-T or cell therapy. For any treatment being considered, your oncologist will explain what is administered at the centre and what, if anything, is coordinated with a partner facility.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is targeted therapy for prostate cancer?
Targeted therapy for prostate cancer refers to drugs designed to work against specific mutations in the cancer cell's DNA — most often in genes involved in DNA repair, such as BRCA1 and BRCA2. The main class in current use is PARP inhibitors, which are recommended by NCCN and ESMO for metastatic castration-resistant prostate cancer when qualifying HRR gene mutations are present. They work through a different mechanism from hormone therapy and are not a replacement for it.
Which gene mutation is most important in prostate cancer?
BRCA2 is the most commonly mutated gene in this context and the most clinically significant, followed by BRCA1. ATM mutations are also targeted by some PARP inhibitors. Other HRR genes — including PALB2, CHEK2 and CDK12 — are tested as part of a comprehensive panel and may affect eligibility for specific clinical trials. MSI-H and TMB-H, though uncommon in prostate cancer, point toward a different treatment path involving immunotherapy rather than PARP inhibitors.
Is genetic testing required before targeted therapy?
Yes. Targeted therapy requires a documented mutation before treatment can be responsibly offered. Treating without testing means accepting real side effects from a drug unlikely to help. NCCN recommends both germline and somatic testing for all patients with metastatic prostate cancer. If testing has not been offered to you, it is entirely reasonable to ask why and to request it at your next appointment.
How long does biomarker testing take?
Most next-generation sequencing panels return results in two to three weeks from when the laboratory receives the sample. If the existing biopsy tissue is too degraded or too small, a repeat biopsy or a liquid biopsy from blood may be needed, which can add time. Ask your oncologist when the sample was sent and when results are expected so you have a timeline rather than waiting without one.
Are PARP inhibitors approved in India?
Olaparib, the most established PARP inhibitor in prostate cancer, has received regulatory approval from CDSCO for qualifying indications and is available in India. Availability is not uniform across all cities and facilities. Your oncologist will advise on which drug is recommended for your specific mutation, where it can be obtained, and whether any access programmes or insurance coverage apply to your situation.
Can targeted therapy stop working over time?
Yes. Like most cancer treatments, PARP inhibitors can lose effectiveness as cancer cells develop mechanisms to work around the pathway they block. This is called acquired resistance. When this happens, your oncologist will reassess your disease and test results to decide on the next step. Clinical trials for patients after PARP inhibitor progression are an important option to discuss at that point, and your team can tell you what is available.